What is the first-line treatment for bipolar disorder?

First-Line Treatment for Bipolar Disorder

Lithium, quetiapine, divalproex, or atypical antipsychotics (aripiprazole, asenapine, risperidone, cariprazine) are first-line pharmacotherapy for bipolar disorder, with lithium remaining the most effective overall mood stabilizer and the preferred long-term agent for preventing both manic and depressive episodes. 1, 2, 3

Treatment Selection by Phase of Illness

Acute Mania

• Lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, or cariprazine—used alone or in combination—constitute first-line treatment for acute manic episodes. 3
• Haloperidol may be used in resource-limited settings when second-generation antipsychotics are unavailable, though first-generation antipsychotics should otherwise be avoided due to higher extrapyramidal symptom risk. 4, 1
• Quetiapine offers a relatively favorable side-effect profile among atypicals, though sedation is common; typical starting dose is 25 mg orally every 12 hours. 4

Acute Bipolar Depression

• First-line options include quetiapine monotherapy, lurasidone plus lithium or divalproex, lithium monotherapy, lamotrigine monotherapy, lurasidone monotherapy, or adjunctive lamotrigine added to existing mood stabilizers. 3
• The olanzapine-fluoxetine combination is FDA-approved for bipolar depression and addresses both depressive and anxiety symptoms. 4
• Antidepressants must never be used as monotherapy in bipolar disorder; if added for comorbid anxiety or depression, the patient must already be receiving at least one mood stabilizer. 4, 5

Maintenance Treatment

• Lithium is FDA-approved for maintenance therapy (age ≥12 years) and remains the preferred long-term mood stabilizer, offering protection against both manic and depressive recurrence as well as reduction in suicidal behavior. 1, 2
• Lamotrigine is FDA-approved for maintenance and offers particular protection against depressive recurrence, making it a valuable complement to lithium's antimanic effect. 4, 1
• Other first-line maintenance options include quetiapine, divalproex, asenapine, and aripiprazole monotherapy or combination treatments. 3
• Maintenance pharmacotherapy should be continued for at least 2 years after the most recent bipolar episode to reduce relapse risk. 1
• The medication regimen that stabilizes the acute phase should generally be continued for 12–24 months, with some patients requiring lifelong therapy. 1

Alternative When Lithium Cannot Be Used

Valproate (divalproex) is the first alternative when lithium is contraindicated or not tolerated, recommended for both acute antimanic control and long-term maintenance in Bipolar I disorder. 1

• Carbamazepine serves as a third-line mood stabilizer when both lithium and valproate are unsuitable, though its evidence base is less robust. 1

Critical Monitoring Requirements

Lithium Monitoring

• Baseline and ongoing laboratory monitoring every 3–6 months is required, including complete blood count, thyroid function, urinalysis, blood urea nitrogen, creatinine, and serum calcium. 1
• Therapeutic lithium serum concentrations should be maintained with regular checks, typically every 3–6 months once stable. 1

Atypical Antipsychotic Monitoring

• Obtain baseline body-mass index, waist circumference, blood pressure, fasting glucose, and fasting lipid panel; monitor BMI monthly for the first 3 months and quarterly thereafter to detect metabolic syndrome, which affects 37% of patients with bipolar disorder. 1, 2
• Regular assessment for extrapyramidal side effects is essential at each visit. 4
• Monitor closely for treatment-emergent suicidality, especially during medication initiation or changes. 4

Common Pitfalls to Avoid

• Antidepressant monotherapy is contraindicated during mixed episodes, manic episodes, and in Bipolar I disorder; always combine with a mood stabilizer (valproate preferred when lithium cannot be used). 4, 1, 5
• Benzodiazepines should not be used as monotherapy for anxiety in bipolar disorder due to disinhibition risk in younger patients and addiction potential. 4
• Discontinuation of prophylactic mood stabilizers must be performed gradually with close monitoring for relapse during the taper; assess mood stability weekly then bi-weekly for 3 months after discontinuation. 1
• More than 50% of patients are non-adherent to treatment, contributing to the 9-year average delay between initial depressive episode and optimal treatment. 2

Adjunctive Psychosocial Treatment

Psychoeducation should be provided routinely alongside any pharmacologic regimen to improve treatment adherence and clinical outcomes. 1

• For children and adolescents with bipolar disorder, family psychoeducation plus skill building (FP + SB) interventions—including family-focused treatment, child- and family-focused CBT, and psychoeducational psychotherapy—constitute well-established adjunctive treatments that increase mood symptom improvement and recovery rates when added to pharmacotherapy. 6